Proteon Therapeutics Inc (NASDAQ:PRTO) Director James E. Flynn purchased 110,557 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was acquired at an average price of $1.75 per share, with a total value of $193,474.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Proteon Therapeutics Inc (NASDAQ:PRTO) traded up $0.02 during trading hours on Wednesday, reaching $1.87. 36,009 shares of the company’s stock were exchanged, compared to its average volume of 107,340. Proteon Therapeutics Inc has a 1-year low of $1.10 and a 1-year high of $2.75.
PRTO has been the subject of several research reports. Robert W. Baird reiterated a “hold” rating and issued a $2.00 price target on shares of Proteon Therapeutics in a research note on Friday, November 10th. HC Wainwright restated a “hold” rating and set a $2.30 price objective on shares of Proteon Therapeutics in a research note on Wednesday, November 8th. Zacks Investment Research lowered shares of Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Finally, Oppenheimer restated a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday, August 16th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. Proteon Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.16.
TRADEMARK VIOLATION WARNING: “James E. Flynn Buys 110,557 Shares of Proteon Therapeutics Inc (PRTO) Stock” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://weekherald.com/2017/12/13/proteon-therapeutics-inc-prto-director-acquires-193474-75-in-stock.html.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.